Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves

March 2014

Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves.

Farxiga (dapagliflozin) is similar to Invokana (canagliflozin).

They increase glucose excretion in the urine by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Colon Cancer more emphasis on improving colon cancer screening
Diabetes whether an ACEI or ARB should always be used first-line for hypertension in diabetes patients
Diabetes Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves
Respiratory & Allergy the new OTC Nasacort Allergy 24HR
Poison Prevention Poisonings in kids due to PRESCRIPTION drugs is on the rise
Headache The new Fioricet capsules are causing a lot of confusion
Drug Testing using urine drug testing for monitoring controlled substances in chronic pain patients
Generics skyrocketing costs of GENERIC drugs
Interactions green tea may interfere with some meds
Women's Health The new drug Duavee (DEW-ah-vee) and new guidelines will raise questions about how to treat menopausal symptoms
NSAIDs controversy about whether naproxen is safer in patients with heart disease than other NSAIDs
Med Safety best practices to further reduce some of the most serious medication errors
Salt Forms how to choose between drugs that come in different salt forms